Novartis announced the launch of once-daily Arcapta Neohaler (indacaterol inhalation powder) 75mcg, for the treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Arcapta Neohaler is not indicated to treat asthma or acute deteriorations of COPD, and should not be used as a rescue medication for acute symptoms.
Arcapta Neohaler 75mcg was studied in two key Phase 3 trials lasting 12 weeks. The primary endpoint results at week 12 showed that Arcapta Neohaler significantly improved lung function (FEV1) at 24 hours compared to placebo.
Arcapta Neohaler is a long-acting beta2-agonist (LABA) indicated for maintenance treatment of airflow obstruction in patients with COPD.
For more information call (888) NOW-NOVA or visit www.pharma.us.novartis.com/info/products.